VenaSeal Sapheon Closure System Pivotal Study (VeClose)

Not Applicable

Completed

Brief Summary: The VeClose pivotal study was a controlled, randomized, prospective, multicenter, pivotal study in which patients with venous reflux in the great saphenous vein (GSV) were treated with either the VenaSeal closure system (VenaSeal SCS) or radiofrequency ablation (RFA) therapy.

Detailed Description: The purpose of the VeClose study was to demonstrate safety and effectiveness of the VenaSeal SCS as being both 1) non-inferior to RFA therapy in achieving anatomical closure of lower extremity superficial truncal veins in patients with venous reflux through endovascular transcatheter embolization with coaptation of the GSV at 3 months, and 2) superior in the reduction of intraprocedural and post procedural pain and symptoms as compared to treatment with RFA.

The study was designed to demonstrate safety of the VenaSeal SCS by follow-up visits that evaluated, via duplex ultrasound and physical exam, the presence of deep vein thrombosis and/or pulmonary embolus.

Recruitment & Eligibility

Inclusion Criteria

Age ≥ 21 years and ≤ 70 years of age at the time of screening
Reflux in the great saphenous vein (GSV) greater than 0.5 sec reflux
One or more of the following symptoms related to the target vein: aching, throbbing, heaviness, fatigue, pruritis, night cramps, restlessness, generalized pain or discomfort, swelling
GSV diameter while standing of 3-12 mm throughout the target vein as measured by Duplex ultrasound
Clinical, etiology, assessment and pathophysiology (CEAP) classification of C2 (if symptomatic) - C4b
Ability to walk unassisted
Ability to attend follow-up visits
Ability to understand the requirements of the study and to provide informed consent

Exclusion Criteria

Life expectancy < 1 year
Active treatment for malignancy other than non-melanoma skin cancer
Symptomatic peripheral arterial disease with ankle-brachial index (ABI) <0.89
Daily use of narcotic or non-steroidal anti-inflammatory pain medications to control pain associated with GSV reflux
Current, regular use of systemic anticoagulation (e.g., warfarin, heparin)
Previous or suspected deep vein thrombosis (DVT) or pulmonary embolus (PE)
Previous superficial thrombophlebitis in GSV
Previous treatment of venous disease in target limb, other than spider vein treatment
Known hypercoagulable disorder
Conditions which prevent vein treatment with either RFA or VenaSeal SCS
Immobilization or inability to ambulate
Pregnant prior to enrollment
Tortuous GSV, which, in the opinion of the investigator, will limit catheter placement or require more than one primary access site
Aneurysm of the target vein with local diameter >12 mm
Significant, incompetent, ipsilateral small saphenous, intersaphenous or anterior accessory great saphenous vein(s)
Known sensitivity to cyanoacrylate (CA) adhesives
Current participation in another clinical study involving an investigational agent or treatment, or within the 30 days prior to enrollment
Patients who require bilateral treatment during the next 3 months
Patients who require additional ipsilateral treatments on the same leg within 3 months following treatment

Primary Outcome Measures

Name	Time	Method
Number of Participants With Complete Closure of the Target Vein at 3 Months	3 months	The primary endpoint of the study was complete closure of the target vein at 3 months after index treatment as judged by the vascular ultrasound laboratory. Complete closure was defined as Doppler ultrasound examination showing closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm.

Secondary Outcome Measures

Name	Time	Method
Intraoperative Pain	During the operative procedure, which was an average of 24 minutes for VenaSeal SCS, 19 minutes for RFA, and 31 minutes for Roll-in group.	After the procedure, pain experienced during the procedure was rated by the subjects on a 0-10 numeric rating scale (NRS) where 0 represents no pain whatsoever and 10 represents worst imaginable pain.
Ecchymosis at Day 3	First follow up visit at day 3	At the Day 3 visit, the investigator visually rated the subject's ipsilateral leg for the occurrence of ecchymosis along the treated area based on a Scale for Ecchymosis Assessment with a 0-5 rating scale, with 0 being the best possible outcome and 5 being the worst possible outcome. The treatment area was defined as the area of skin overlying the treated vein, excluding the 5 cm of skin immediately adjacent to the access site. The rating scale was based on the percentage of ecchymosis of the treated area according to the following criteria: 0 rating = no ecchymosis, 1. rating = less than 25% ecchymosis, 2. rating = 25-50% ecchymosis, 3. rating = 50-75% ecchymosis, 4. rating = 75-100% ecchymosis, 5. rating = extension of ecchymosis above or below the treated area.

Locations (10): Morrison Vein Institute
🇺🇸
Scottsdale, Arizona, United States
GBK Cosmetic Laser Dermatology
🇺🇸
San Diego, California, United States
Radiology Imaging Associates (RIA)
🇺🇸
Greenwood Village, Colorado, United States
Vein Clinics of America
🇺🇸
Oakbrook Terrace, Illinois, United States
Prairie Education & Research Cooperative
🇺🇸
Springfield, Illinois, United States
MD Laser Skin & Vein Institute
🇺🇸
Hunt Valley, Maryland, United States
Vein Institute of Buffalo
🇺🇸
North Tonawanda, New York, United States
Inovia Vein Specialty Center
🇺🇸
Bend, Oregon, United States
Sentara Vascular Specialist
🇺🇸
Virginia Beach, Virginia, United States
Lake Washington Vascular
🇺🇸
Bellevue, Washington, United States
Morrison Vein Institute
🇺🇸Scottsdale, Arizona, United States